Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
475.91
-2.67 (-0.56%)
At close: Oct 28, 2025, 4:00 PM EDT
476.02
+0.11 (0.02%)
After-hours: Oct 28, 2025, 6:45 PM EDT
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,104,019
Profits / Employee
-$143,089
Market Cap
62.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,230 | 130 | 6.19% |
| Dec 31, 2023 | 2,100 | 98 | 4.90% |
| Dec 31, 2022 | 2,002 | 337 | 20.24% |
| Dec 31, 2021 | 1,665 | 212 | 14.59% |
| Dec 31, 2020 | 1,453 | 130 | 9.83% |
| Dec 31, 2019 | 1,323 | 258 | 24.23% |
| Dec 31, 2018 | 1,065 | 316 | 42.19% |
| Dec 31, 2017 | 749 | 235 | 45.72% |
| Dec 31, 2016 | 514 | 145 | 39.30% |
| Dec 31, 2015 | 369 | 113 | 44.14% |
| Dec 31, 2014 | 256 | 91 | 55.15% |
| Dec 31, 2013 | 165 | 36 | 27.91% |
| Dec 31, 2012 | 129 | 13 | 11.21% |
| Dec 31, 2011 | 116 | -56 | -32.56% |
| Dec 31, 2010 | 172 | -6 | -3.37% |
| Dec 31, 2009 | 178 | 8 | 4.71% |
| Dec 31, 2008 | 170 | 41 | 31.78% |
| Dec 31, 2007 | 129 | 7 | 5.74% |
| Dec 31, 2006 | 122 | 28 | 29.79% |
| Dec 31, 2005 | 94 | 23 | 32.39% |
| Dec 31, 2004 | 71 | 11 | 18.33% |
| Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALNY News
- 12 days ago - Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results - Business Wire
- 17 days ago - Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
- 27 days ago - Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
- 4 weeks ago - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
- 5 weeks ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript - Seeking Alpha
- 5 weeks ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire
- 6 weeks ago - Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes - Business Wire